S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)

RAPT Therapeutics (RAPT) Stock Price, News & Analysis

$8.77
-0.16 (-1.79%)
(As of 10:27 AM ET)
Today's Range
$8.71
$9.00
50-Day Range
$6.87
$26.45
52-Week Range
$6.86
$27.35
Volume
39,445 shs
Average Volume
1.25 million shs
Market Capitalization
$305.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.67

RAPT Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
187.4% Upside
$25.67 Price Target
Short Interest
Bearish
9.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
-0.01mentions of RAPT Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$20,456 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.21) to ($2.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.34 out of 5 stars

Medical Sector

183rd out of 939 stocks

Pharmaceutical Preparations Industry

74th out of 436 stocks

RAPT stock logo

About RAPT Therapeutics Stock (NASDAQ:RAPT)

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

RAPT Stock Price History

RAPT Stock News Headlines

RAPT Apr 2024 10.000 put
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
RAPT Oct 2024 5.000 call
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
RAPT May 2024 17.500 put
UBS Downgrades RAPT Therapeutics (RAPT)
Rapt Therapeutics just downgraded at Leerink, here's why
What's Going On With RAPT Therapeutics Stock On Wednesday?
Rapt Therapeutics just downgraded at JPMorgan, here's why
Rapt Therapeutics just downgraded at Cantor Fitzgerald, here's why
See More Headlines
Receive RAPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/27/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RAPT
Fax
N/A
Employees
131
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$25.67
High Stock Price Target
$41.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+189.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-116,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.53 million
Book Value
$4.27 per share

Miscellaneous

Free Float
32,884,000
Market Cap
$310.76 million
Optionable
Optionable
Beta
0.47

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Brian Russell Wong M.D. (Age 52)
    Ph.D., CEO, President & Director
    Comp: $797.5k
  • Mr. Rodney K. B. Young (Age 61)
    CFO, Principal Accounting Officer & Secretary
    Comp: $585k
  • Dr. William HoDr. William Ho (Age 58)
    Chief Medical Officer
    Comp: $590k
  • Steve Young Ph.D.
    Vice President of Technology
  • Dr. Dirk G. Brockstedt Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $490.25k
  • Mr. Michael Listgarten
    General Counsel
  • Ms. Gwen R. Carscadden (Age 63)
    Chief Human Resources Officer
  • Dr. Paul Kassner (Age 57)
    Senior Vice President of Quantitative & Computational Biology
  • Dr. David Wustrow (Age 65)
    Senior Vice President of Drug Discovery & Preclinical Development
  • Ms. Jennifer Nicholson
    Senior Vice President of Regulatory Affairs & Quality Assurance

RAPT Stock Analysis - Frequently Asked Questions

Should I buy or sell RAPT Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RAPT shares.
View RAPT analyst ratings
or view top-rated stocks.

What is RAPT Therapeutics' stock price target for 2024?

12 analysts have issued 12-month price objectives for RAPT Therapeutics' shares. Their RAPT share price targets range from $10.00 to $41.00. On average, they anticipate the company's share price to reach $25.67 in the next year. This suggests a possible upside of 187.4% from the stock's current price.
View analysts price targets for RAPT
or view top-rated stocks among Wall Street analysts.

How have RAPT shares performed in 2024?

RAPT Therapeutics' stock was trading at $24.85 at the start of the year. Since then, RAPT stock has decreased by 64.1% and is now trading at $8.93.
View the best growth stocks for 2024 here
.

Are investors shorting RAPT Therapeutics?

RAPT Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 3,300,000 shares, an increase of 32.5% from the February 29th total of 2,490,000 shares. Based on an average daily volume of 1,210,000 shares, the short-interest ratio is currently 2.7 days.
View RAPT Therapeutics' Short Interest
.

When is RAPT Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RAPT earnings forecast
.

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.05.

What ETFs hold RAPT Therapeutics' stock?

ETFs with the largest weight of RAPT Therapeutics (NASDAQ:RAPT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What is Brian Wong's approval rating as RAPT Therapeutics' CEO?

8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

When did RAPT Therapeutics IPO?

RAPT Therapeutics (RAPT) raised $39 million in an initial public offering on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO.

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.92%), Price T Rowe Associates Inc. MD (9.92%), Perceptive Advisors LLC (6.22%), Vanguard Group Inc. (5.98%), Vanguard Group Inc. (5.91%) and Great Point Partners LLC (3.20%). Insiders that own company stock include Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends
.

How do I buy shares of RAPT Therapeutics?

Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RAPT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners